Related Experiment Videos
Response and progression in recurrent malignant glioma
K R Hess1, E T Wong, K A Jaeckle
1Department of Biomathematics, Box 237, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Neuro-Oncology
|September 12, 2001
Summary
In recurrent glioma patients, achieving a response to chemotherapy significantly reduces progression rates. This finding highlights the importance of treatment response in managing recurrent brain tumors.
Area of Science:
- Neuro-oncology
- Clinical Trials
- Cancer Research
Background:
- Recurrent glioma poses a significant challenge in neuro-oncology.
- Evaluating treatment efficacy in recurrent glioma is crucial for patient outcomes.
Purpose of the Study:
- To investigate the relationship between treatment response and disease progression in patients with recurrent glioma.
- To analyze the impact of response on progression-free survival and failure rates.
Main Methods:
- Retrospective analysis of 375 patients from 8 phase II chemotherapy trials for recurrent glioma.
- Inclusion of patients with recurrent glioblastoma multiforme and anaplastic astrocytoma.
- Statistical analysis using Cox proportional hazards regression with response as a time-dependent covariate.
Main Results:
- Overall response rate was 9% (complete or partial response).
- Patients achieving response showed significantly lower failure rates (hazard ratio 0.5).
- Progression-free survival at 52 weeks was higher for responders (48%) compared to non-responders (28%).
Conclusions:
- Treatment response in recurrent glioma is associated with a substantial reduction in progression rates.
- These findings underscore the prognostic significance of treatment response in recurrent glioma management.
- Chemotherapy response can be a key indicator for improved outcomes in recurrent glioma patients.